Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of Enhertu in reducing the number of women who lose their lives to breast cancer in (a) Newcastle-under-Lyme constituency and b) England.

Whilst we have made no specific assessment, the clinical trial evidence considered by the National Institute for Health and Care Excellence (NICE) shows that Enhertu increases how long people live and how long they have before their cancer gets worse compared with chemotherapy treatments used for HER2‑negative breast cancer. It is not, however, a curative treatment.

We understand from NICE that it is estimated that approximately 1,000 women in England would have been eligible for treatment with Enhertu, if NICE had been able to recommend it for use in the treatment of HER2-low breast cancer. Information at constituency level is not held.